Celcuity Inc. (CELC) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Celcuity Inc. is a clinical-stage biotechnology company developing targeted therapies for solid tumors, led by its candidate gedatolisib (a PI3K/AKT/mTOR inhibitor). This report covers the quarterly period ended June 30, 2025. The company has not generated revenue to date and remains in a pre-commercial development phase.
Key Financial Metrics (Six Months Ended June 30, 2025)
| Metric | Value (in thousands) |
|---|---|
| Revenue | $0 |
| Net Loss | $(82,265) |
| Net Loss Per Share (Diluted) | $(1.90) |
| Operating Expenses | $80,142 |
| Research & Development (R&D) | $72,449 |
| General & Administrative (G&A) | $7,693 |
| Cash & Cash Equivalents (End of Period) | $46,354 |
| Short-Term Investments | $122,032 |
| Total Liquidity | $168,386 |
| Long-Term Debt (Net) | $99,276 |
| Accumulated Deficit | $(354,120) |
Material Changes vs. Prior Period
- Increased Burn Rate: Net loss for the six months ended June 30, 2025, increased by 81% to $82.3 million compared to $45.3 million in the same period in 2024.
- R&D Expense Surge: R&D expenses rose 68% to $72.4 million. This increase was driven by higher clinical trial costs ($11.8 million increase), increased employee/consulting expenses ($12.5 million increase), and a $5.0 million accrual for a probable Pfizer license milestone payment.
- G&A Expense Growth: G&A expenses increased 112% to $7.7 million, primarily due to higher employee-related costs and professional fees.
- Interest Expense: Interest expense increased 74% to $6.4 million, largely due to the incremental funding of Term Loan C in May 2024.
- Investment Portfolio: Investments decreased from $212.6 million (Dec 31, 2024) to $122.0 million (June 30, 2025) as the company utilized cash for operations, though net cash provided by investing activities was positive ($90.1 million) due to maturities exceeding purchases.
Outlook, Management Commentary, and Subsequent Events
Clinical Milestones:
- VIKTORIA-1 (Phase 3): Topline data for the PIK3CA wild-type cohort was reported in July 2025, showing statistically significant improvements in Progression-Free Survival (PFS) for both the gedatolisib triplet and doublet regimens compared to fulvestrant. The company expects to submit a New Drug Application (NDA) to the FDA in Q4 2025.
- VIKTORIA-2 (Phase 3): First patient dosed in July 2025 for first-line treatment of HR+/HER2- advanced breast cancer.
- CELC-G-201 (Phase 1b/2): Topline data for metastatic castration-resistant prostate cancer showed a 66% six-month radiographic PFS with a favorable safety profile.
Significant Subsequent Events (Post-June 30, 2025):
- Equity Offering: In late July 2025, the company completed a public offering of common stock and pre-funded warrants, raising approximately $91.6 million in net proceeds.
- Convertible Notes Offering: In late July/early August 2025, the company issued $201.25 million aggregate principal amount of 2.750% Convertible Senior Notes due 2031, raising approximately $194.9 million in net proceeds.
- Debt Facility: The company achieved the Term D Milestone under its A&R Loan Agreement, making it eligible to draw an additional $30.0 million, which it intends to draw in late August 2025.
Liquidity Outlook: Management believes current cash, investments, and proceeds from recent financings will fund operations through 2027.
Investor Verification Checklist
- NDA Submission Timeline: Verify the company's ability to submit the NDA for gedatolisib in Q4 2025 as planned, following the positive VIKTORIA-1 data.
- Debt Covenants: Review the financial covenants in the A&R Loan Agreement and the Convertible Notes indenture to ensure compliance, particularly regarding liquidity percentages and interest coverage.
- Capitalization Dilution: Assess the impact of the recent equity offering and the conversion features of the new $201.25 million convertible notes on existing shareholders.
- PIK Interest Impact: Monitor the Payment-in-Kind (PIK) interest accruals on the existing term loan, which increase the principal balance over time.
- Commercial Readiness: Evaluate the company's preparedness for commercial launch (sales force, manufacturing scale-up) given the anticipated FDA approval timeline.